KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Non Operating Income: 2019-2025

Historic Non Operating Income for Royalty Pharma (RPRX) over the last 7 years, with Sep 2025 value amounting to $17.1 million.

  • Royalty Pharma's Non Operating Income fell 76.07% to $17.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$230.0 million, marking a year-over-year decrease of 235.13%. This contributed to the annual value of $38.4 million for FY2024, which is 81.55% down from last year.
  • As of Q3 2025, Royalty Pharma's Non Operating Income stood at $17.1 million, which was up 114.31% from -$119.2 million recorded in Q2 2025.
  • Royalty Pharma's 5-year Non Operating Income high stood at $113.8 million for Q2 2022, and its period low was -$127.4 million during Q4 2022.
  • Its 3-year average for Non Operating Income is $3.9 million, with a median of $17.1 million in 2025.
  • Its Non Operating Income has fluctuated over the past 5 years, first plummeted by 289.73% in 2021, then spiked by 342.75% in 2024.
  • Over the past 5 years, Royalty Pharma's Non Operating Income (Quarterly) stood at -$99.7 million in 2021, then dropped by 27.70% to -$127.4 million in 2022, then surged by 182.19% to $104.7 million in 2023, then slumped by 125.95% to -$27.2 million in 2024, then crashed by 76.07% to $17.1 million in 2025.
  • Its Non Operating Income stands at $17.1 million for Q3 2025, versus -$119.2 million for Q2 2025 and -$100.7 million for Q1 2025.